Mebendazole Ennogen Ip Ltd

Mebendazole, the active ingredient in Mebendazole Ennogen Ip Ltd, is a benzimidazole presented as an oral dosage form for oral use. It treats intestinal helminth infections such as Ascaris lumbricoides, Trichuris trichiura, and hookworm in patients of various ages.

GNH USA supplies Mebendazole Ennogen Ip Ltd as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides regulatory documentation to support global distribution. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Mebendazole is an anthelmintic drug that targets intestinal helminths, providing parasite eradication in affected patients. - Ascaris lumbricoides infection: eliminates adult worms and reduces egg output, helping resolve ascariasis symptoms. - Trichuris trichiura infection: clears whipworm infestation and improves gastrointestinal health. - Hookworm infection: removes hookworms from the intestine, alleviating anemia and abdominal discomfort.

Mebendazole may cause adverse reactions, ranging from mild to severe, which should be monitored during therapy.

Common Side Effects: - Abdominal pain: mild discomfort or cramps in the stomach area. - Nausea: feeling of queasiness that may lead to vomiting. - Headache: transient head pain without neurological signs. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury. - Severe allergic reaction: hives, swelling, or anaphylaxis requiring immediate medical attention. - Blood dyscrasias: neutropenia, agranulocytosis, or other abnormal blood counts. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.

Before initiating Mebendazole therapy, healthcare professionals should consider several precautionary measures to ensure safe use. - Assess contraindications: verify no known hypersensitivity to benzimidazoles. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Use cautiously in children: adjust dosing according to pediatric guidelines. - Review concomitant medications: check for drugs that may alter Mebendazole metabolism. - Educate patients: inform about possible gastrointestinal upset and when to seek help. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mebendazole can interact with other medicines, affecting its absorption or metabolism; awareness of these interactions helps avoid therapeutic failures or toxicity.

Major Interactions (Avoid): - Cimetidine: increases Mebendazole plasma levels, raising risk of toxicity. - Carbamazepine: induces hepatic enzymes, reducing Mebendazole effectiveness. - Ritonavir: strong CYP3A4 inhibition, markedly elevating drug concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring coagulation monitoring. - Oral contraceptives: reduced efficacy, advise additional contraceptive methods. - Antacids containing aluminum or magnesium: may decrease absorption, separate dosing by at least 2 hours.